Sanofi-aventis announces the termination of development and commercialization agreement for S-1 with Taiho Pharmaceutical
This termination follows the announcement by Taiho Pharmaceutical Co., Ltd of the Phase III study results which evaluated the efficacy and safety of the oral anti-cancer agent S-1 in a multicentric trial in patients with locally advanced gastric cancer.
S-1 is an oral fluorouracil anticancer product that combines 3 pharmacological agents: tegafur which is a pro-drug of 5 fluoro-uracil; gimeracil (5-chloro-2,4 dihydropyridine (CDHP)) which inhibits dihydropyrimidine dehydrogenase (DPD) enzyme activity; and oteracil (potassium oxonate (Oxo)) a gastrointestinal side effects corrector.
S-1 has been commercialized in Japan by Taiho Pharmaceutical since 1999 for the treatment of gastric, colorectal, head and neck, non-small cell lung, metastatic breast and pancreas cancers.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.